| Literature DB >> 18982476 |
Tomohiko Yamane1, Osami Daimaru, Satoshi Ito, Takeshi Nagata, Kazuhiko Yoshiya, Nobuyuki Fukaya, Shinichi Ito, Teruhiko Imai, Hideo Uchida.
Abstract
Drug-induced pneumonitis is a serious and an unpredictable side effect of chemotherapy in patients with malignant lymphoma. We present the case of a 51-year-old man who developed drug-induced pneumonitis during chemotherapy for non-Hodgkin's lymphoma in which pneumonitis was detected earlier by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) than by high-resolution computed tomography (HRCT). After five courses of chemotherapy, 18F-FDG-PET was performed for assessing residual lesions, and diffuse lung uptake was incidentally observed. No symptoms were present, and HRCT performed immediately following PET revealed no abnormalities. Mild dyspnea appeared 3 days after PET, and additional HRCT revealed patchy ground-glass opacities disseminated with the appearance of interlobular septum thickening. Drug-induced pneumonitis was finally diagnosed, and treatment was initiated. 18F-FDG-PET can be an imaging modality for detecting drug-induced pneumonitis at an extremely early stage in which HRCT is incapable of revealing any abnormal changes.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18982476 DOI: 10.1007/s12149-008-0183-7
Source DB: PubMed Journal: Ann Nucl Med ISSN: 0914-7187 Impact factor: 2.668